Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rahul A Sheth

Showing results (121-130 of 131) with videos related to

Pageof 14
Sort By:
Science Advances|March 2, 2022
Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumorsAmanda M Nash, Maria I Jarvis, Samira Aghlara-Fotovat, et al.
Cancer Research Communications|August 29, 2024
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder CancerMatthew T Campbell, Amishi Y Shah, Pavlos Msaouel, et al.
Nature Communications|November 5, 2021
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinomaMatthew T Campbell, Surena F Matin, Alda L Tam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2025
CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical ValidationSandra L Grimm, Menuka Karki, Kyle A Blum, et al.
The Oncologist|August 7, 2015
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic CholangiocarcinomaLipika Goyal, Aparna Govindan, Rahul A Sheth, et al.
Nature Communications|January 10, 2025
Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trialPavlos Msaouel, Kai Yu, Ying Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2025
Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid TumorsBlessie Elizabeth Nelson, Filip Janku, Siqing Fu, et al.
Journal for Immunotherapy of Cancer|April 19, 2024
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic diseaseJason J Luke, Diwakar Davar, Robert H Andtbacka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2026
Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary CarcinomaKai Yu, Rebecca S Tidwell, Tharakeswara K Bathala, et al.
Cell Reports. Medicine|October 31, 2025
Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profilingPavlos Msaouel, Nizar M Tannir, Funda Meric-Bernstam, et al.
Pageof 14

Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
Science Advances|March 2, 2022
Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumorsAmanda M Nash, Maria I Jarvis, Samira Aghlara-Fotovat, et al.
Cancer Research Communications|August 29, 2024
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder CancerMatthew T Campbell, Amishi Y Shah, Pavlos Msaouel, et al.
Nature Communications|November 5, 2021
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinomaMatthew T Campbell, Surena F Matin, Alda L Tam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2025
CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical ValidationSandra L Grimm, Menuka Karki, Kyle A Blum, et al.
The Oncologist|August 7, 2015
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic CholangiocarcinomaLipika Goyal, Aparna Govindan, Rahul A Sheth, et al.
Nature Communications|January 10, 2025
Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trialPavlos Msaouel, Kai Yu, Ying Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2025
Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid TumorsBlessie Elizabeth Nelson, Filip Janku, Siqing Fu, et al.
Journal for Immunotherapy of Cancer|April 19, 2024
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic diseaseJason J Luke, Diwakar Davar, Robert H Andtbacka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2026
Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary CarcinomaKai Yu, Rebecca S Tidwell, Tharakeswara K Bathala, et al.
Cell Reports. Medicine|October 31, 2025
Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profilingPavlos Msaouel, Nizar M Tannir, Funda Meric-Bernstam, et al.
Pageof 14